Bio-Techne Corporation has opened a new manufacturing facility in Bristol, United Kingdom, for Good Manufacturing Practice (GMP) grade small molecules. This expansion supports the rapidly growing cell therapy market and addresses a key industry challenge: establishing scalable, reproducible manufacturing processes.
The 10,000-square-foot facility includes five ISO-8 and two ISO-7 multifunctional cleanrooms dedicated to GMP small molecule manufacturing and product handling. It is designed to meet the rigorous standards required for advanced cell therapy manufacturing, enhancing Bio-Techne’s ability to provide customers with high-quality GMP materials supported by robust quality systems and reliable global supply.
Kim Kelderman, CEO of Bio-Techne, stated the investment demonstrates the company’s commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and bring transformative therapies to patients.
This Bristol expansion is part of Bio-Techne’s broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow, alongside operations in Minneapolis, St Paul, and a strategic relationship with Wilson Wolf Corporation.
Bio-Techne offers an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support, helping customers transition seamlessly from research through clinical development and commercial production.
Cell therapy developers face mounting pressure to reduce variability, standardize manufacturing processes, and scale production efficiently. Bio-Techne addresses these challenges through high-quality GMP materials, scalable manufacturing solutions, and analytical technologies designed to improve consistency and accelerate development timelines.
The Bristol facility is fully operational and is manufacturing GMP-grade small molecules that support customers developing next-generation cell therapies worldwide.